MA27034A1 - Formulations auto-emulsionnables d'inhibiteurs de la proteine de transfert d'ester de cholesteryle - Google Patents

Formulations auto-emulsionnables d'inhibiteurs de la proteine de transfert d'ester de cholesteryle

Info

Publication number
MA27034A1
MA27034A1 MA27430A MA27430A MA27034A1 MA 27034 A1 MA27034 A1 MA 27034A1 MA 27430 A MA27430 A MA 27430A MA 27430 A MA27430 A MA 27430A MA 27034 A1 MA27034 A1 MA 27034A1
Authority
MA
Morocco
Prior art keywords
emulsible
formulations
self
transfer protein
cholesteryl ester
Prior art date
Application number
MA27430A
Other languages
English (en)
Inventor
Michael Jon Gumkowski
Michael Ellis Perlman
Sharad Balasaheb Murdande
Franco LOMBARDO
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA27034A1 publication Critical patent/MA27034A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Colloid Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA27430A 2001-06-21 2003-12-10 Formulations auto-emulsionnables d'inhibiteurs de la proteine de transfert d'ester de cholesteryle MA27034A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30002801P 2001-06-21 2001-06-21

Publications (1)

Publication Number Publication Date
MA27034A1 true MA27034A1 (fr) 2004-12-20

Family

ID=23157363

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27430A MA27034A1 (fr) 2001-06-21 2003-12-10 Formulations auto-emulsionnables d'inhibiteurs de la proteine de transfert d'ester de cholesteryle

Country Status (33)

Country Link
US (2) US6962931B2 (fr)
EP (1) EP1453544A2 (fr)
JP (1) JP2005500314A (fr)
KR (1) KR20040015746A (fr)
CN (1) CN1635911A (fr)
AP (1) AP2002002559A0 (fr)
AR (1) AR034599A1 (fr)
BG (1) BG108486A (fr)
BR (1) BR0210505A (fr)
CA (1) CA2455288A1 (fr)
CR (1) CR7163A (fr)
CZ (1) CZ20033341A3 (fr)
EA (1) EA200301139A1 (fr)
EC (1) ECSP034875A (fr)
EE (1) EE200400024A (fr)
GT (1) GT200200124A (fr)
HN (1) HN2002000153A (fr)
HU (1) HUP0400263A2 (fr)
IL (1) IL158765A0 (fr)
IS (1) IS7014A (fr)
MA (1) MA27034A1 (fr)
MX (1) MXPA04000014A (fr)
NO (1) NO20035632L (fr)
OA (1) OA12619A (fr)
PA (1) PA8548601A1 (fr)
PE (1) PE20030128A1 (fr)
PL (1) PL368850A1 (fr)
SK (1) SK15172003A3 (fr)
SV (1) SV2003001103A (fr)
TN (1) TNSN03139A1 (fr)
UY (1) UY27344A1 (fr)
WO (1) WO2003000295A2 (fr)
ZA (1) ZA200308561B (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1154759B1 (fr) * 1998-12-30 2008-08-13 Dexcel Ltd. Concentre dispersable destine a l'administration d'une cyclosporine
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
JP4031232B2 (ja) * 2001-11-09 2008-01-09 カプスゲル・ジャパン株式会社 新規カプセル
ATE395044T1 (de) 2002-02-01 2008-05-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
AU2003219942A1 (en) * 2002-03-01 2003-09-16 Cesi Chemical, A Flotek Company Composition and process for well cleaning
US20040175341A1 (en) * 2003-03-04 2004-09-09 Manning Monna Marie Microemulsion for cosmetic or pharmaceutical use containing an active ingredient
MXPA05009848A (es) * 2003-03-17 2005-12-06 Japan Tobacco Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia del ester de colesterilo.
CN101036636A (zh) * 2003-03-17 2007-09-19 日本烟草产业株式会社 提高s－[2－([[1－(2－乙基丁基)环己基]羰基]氨基)苯基]－2－甲基丙硫代酸酯口服生物利用度的方法
WO2004082675A1 (fr) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Procede pour accroitre la biodisponibilite orale de s- [2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] -2-methylpropanethioate
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
JP2007501218A (ja) * 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
JP2007507481A (ja) * 2003-09-30 2007-03-29 ファイザー・プロダクツ・インク Ｃｅｔｐ阻害薬及びその代謝産物
WO2005037796A1 (fr) * 2003-10-08 2005-04-28 Eli Lilly And Company Composes et techniques de traitement de la dyslipidemie
US20050220866A1 (en) * 2004-04-02 2005-10-06 Dr. Reddy's Laboratories Limited Novel capsule formulations of etoposide for oral use
WO2006069162A1 (fr) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Nouveaux composes heterocycliques et leurs compositions pharmaceutiques
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2006073973A2 (fr) 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Nouveaux dérivés de benzylamine en tant qu'inhibiteurs de cetp
WO2006085217A2 (fr) * 2005-02-08 2006-08-17 Pfizer Products Inc. Adsorbes solides de medicaments hydrophobes
US7623458B2 (en) * 2005-09-30 2009-11-24 The Boeing Company System and method for providing integrated services across cryptographic boundaries in a network
EP1965764B1 (fr) 2005-12-05 2011-07-13 Merck Sharp & Dohme Corp. Formulations d'inhibiteur de cetp
JP5844954B2 (ja) * 2005-12-31 2016-01-20 天士力製薬集団株式会社 アリタソウの抽出物を含有する医薬組成物、それらの製造方法
US20080026050A1 (en) * 2006-06-30 2008-01-31 Rajan Gupta Solid dose formulations of a thrombin receptor antagonist
EP1961412A1 (fr) 2006-12-27 2008-08-27 LEK Pharmaceuticals D.D. Systèmes auto-microémulsifiants pour l'administration de médicaments
US9222013B1 (en) 2008-11-13 2015-12-29 Cesi Chemical, Inc. Water-in-oil microemulsions for oilfield applications
EP2373344B1 (fr) * 2008-12-08 2016-03-30 F. Hoffmann-La Roche AG Administration conjointe
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
CA2690490C (fr) * 2010-01-19 2012-06-26 Accucaps Industries Limited Formulations pharmaceutiques de loratadine pour encapsulation et combinaisons associees
WO2012159960A1 (fr) * 2011-05-20 2012-11-29 Aventis Pharmaceuticals Inc. Composition pharmaceutique contenant de la fexofénadine
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
MX352074B (es) 2011-09-27 2017-11-08 Dr Reddys Laboratories Ltd Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.
WO2013059729A1 (fr) 2011-10-21 2013-04-25 First Tech International Limited Compositions de tocotriénol
EP2838970B1 (fr) 2012-04-15 2016-12-28 Flotek Chemistry, LLC Formulations de tensio-actif pour injection de mousse
US11407930B2 (en) 2012-05-08 2022-08-09 Flotek Chemistry, Llc Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons
US9200192B2 (en) 2012-05-08 2015-12-01 Cesi Chemical, Inc. Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons
US20160000799A1 (en) * 2013-02-21 2016-01-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
US9868893B2 (en) 2013-03-14 2018-01-16 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US10287483B2 (en) 2013-03-14 2019-05-14 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells comprising a terpene alcohol
US9884988B2 (en) 2013-03-14 2018-02-06 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US9321955B2 (en) 2013-06-14 2016-04-26 Flotek Chemistry, Llc Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
US11254856B2 (en) 2013-03-14 2022-02-22 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US10053619B2 (en) 2013-03-14 2018-08-21 Flotek Chemistry, Llc Siloxane surfactant additives for oil and gas applications
US10000693B2 (en) 2013-03-14 2018-06-19 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US9464223B2 (en) 2013-03-14 2016-10-11 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US9428683B2 (en) 2013-03-14 2016-08-30 Flotek Chemistry, Llc Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
US10941106B2 (en) 2013-03-14 2021-03-09 Flotek Chemistry, Llc Methods and compositions incorporating alkyl polyglycoside surfactant for use in oil and/or gas wells
US10577531B2 (en) 2013-03-14 2020-03-03 Flotek Chemistry, Llc Polymers and emulsions for use in oil and/or gas wells
US10421707B2 (en) 2013-03-14 2019-09-24 Flotek Chemistry, Llc Methods and compositions incorporating alkyl polyglycoside surfactant for use in oil and/or gas wells
US11180690B2 (en) 2013-03-14 2021-11-23 Flotek Chemistry, Llc Diluted microemulsions with low surface tensions
US10590332B2 (en) 2013-03-14 2020-03-17 Flotek Chemistry, Llc Siloxane surfactant additives for oil and gas applications
US10717919B2 (en) 2013-03-14 2020-07-21 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US9068108B2 (en) 2013-03-14 2015-06-30 Cesi Chemical, Inc. Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
CN104706689A (zh) * 2013-12-16 2015-06-17 天津迈迪瑞康生物医药科技有限公司 一种鸦胆子油脂肪乳浓缩液、其制备方法及用途
CN104706587A (zh) * 2013-12-16 2015-06-17 天津迈迪瑞康生物医药科技有限公司 一种依托咪酯脂肪乳浓缩液、其制备方法及用途
CN104706586A (zh) * 2013-12-16 2015-06-17 天津迈迪瑞康生物医药科技有限公司 一种丁酸氯维地平脂肪乳浓缩液、其制备方法及用途
US9890624B2 (en) 2014-02-28 2018-02-13 Eclipse Ior Services, Llc Systems and methods for the treatment of oil and/or gas wells with a polymeric material
US9890625B2 (en) 2014-02-28 2018-02-13 Eclipse Ior Services, Llc Systems and methods for the treatment of oil and/or gas wells with an obstruction material
CA2891278C (fr) 2014-05-14 2018-11-06 Cesi Chemical, Inc. Methodes et compositions destinees aux puits de petrole ou de gaz
US10294757B2 (en) 2014-07-28 2019-05-21 Flotek Chemistry, Llc Methods and compositions related to gelled layers in oil and/or gas wells
US11331376B2 (en) 2014-11-04 2022-05-17 Innopharmax, Inc. Oral administration of unstable or poorly-absorbed drugs
CN104490775A (zh) * 2014-12-20 2015-04-08 长沙佰顺生物科技有限公司 一种安塞曲匹脂肪乳及其制备方法
CN104546710A (zh) * 2014-12-20 2015-04-29 长沙佰顺生物科技有限公司 一种安塞曲匹纳米乳及其制备方法
KR101590072B1 (ko) * 2014-12-23 2016-01-29 한미약품 주식회사 두타스테라이드를 포함하는 자가유화 약물전달 시스템용 조성물
AU2016267685A1 (en) 2015-05-28 2017-12-07 Dr. Reddy's Laboratories Ltd. Oral composition of celecoxib for treatment of pain
SG10202011827YA (en) 2016-04-15 2021-01-28 Novira Therapeutics Inc Combinations and methods comprising a capsid assembly inhibitor
US10934472B2 (en) 2017-08-18 2021-03-02 Flotek Chemistry, Llc Compositions comprising non-halogenated solvents for use in oil and/or gas wells and related methods
US11053433B2 (en) 2017-12-01 2021-07-06 Flotek Chemistry, Llc Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
JP7433252B2 (ja) 2018-03-14 2024-02-19 キャンディ・セラピューティクス・リミテッド Ｎｋ－１／ｎｋ－３受容体二重アンタゴニストを含む新規な医薬製剤
CA3090125A1 (fr) 2018-03-14 2019-09-19 Janssen Sciences Ireland Unlimited Company Schema posologique de modulateur d'assemblage de capside
EP3886813B1 (fr) * 2018-11-26 2023-03-22 Hepion Pharmaceuticals, Inc. Formulations pharmaceutiques d'analogues de cyclosporine
BR112021018817A2 (pt) 2019-04-11 2021-11-23 Scherer Technologies Llc R P Formulação para suprimento oral de proteínas, peptídeos e moléculas pequenas com pouca permeabilidade
CN110252395B (zh) * 2019-07-01 2020-10-16 湖北远大生命科学与技术有限责任公司 一种用于制备高纯度牛磺酸的催化剂及其应用
US11104843B2 (en) 2019-10-10 2021-08-31 Flotek Chemistry, Llc Well treatment compositions and methods comprising certain microemulsions and certain clay control additives exhibiting synergistic effect of enhancing clay swelling protection and persistency
FR3110852B1 (fr) * 2020-05-27 2024-03-15 Centre Nat Rech Scient Emulsions pour liberation controlee de medicaments
US11512243B2 (en) 2020-10-23 2022-11-29 Flotek Chemistry, Llc Microemulsions comprising an alkyl propoxylated sulfate surfactant, and related methods
CA3144079A1 (fr) 2020-12-28 2022-06-28 Biodelivery Sciences International, Inc. Methodes de traitement de la douleur
CN119259277B (zh) * 2024-11-26 2026-04-03 昆明理工大学 一种氮杂环硫酮类化合物的应用
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI65914C (fi) 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
GB9208712D0 (en) 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
WO1995031979A1 (fr) 1994-05-19 1995-11-30 R.P. Scherer International Corporation Solutions d'acides alcanoiques a substitution aryle ou heteroaryle dans des solvants lipophiles, et capsules de gelatine molle contenant de telles solutions
JPH11504028A (ja) 1995-04-24 1999-04-06 イースム リサーチ ディベロップメント カンパニー オブ ザ ヒーブル ユニバーシティ オブ エルサレム 油／水エマルジョンを作り出す自己乳化性配合物
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
CN1494920A (zh) 1996-06-19 2004-05-12 ��˹��ŵ�� 含有环孢菌素的软胶囊制剂
US5958876A (en) 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
JP2894445B2 (ja) * 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
AU9297798A (en) * 1997-09-16 1999-04-05 G.D. Searle & Co. Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity
DE19741399A1 (de) 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
US6063762A (en) 1997-12-05 2000-05-16 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
AU3285499A (en) * 1998-02-13 1999-08-30 G.D. Searle & Co. Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
JP2002525350A (ja) * 1998-09-25 2002-08-13 モンサント カンパニー コレステロールエステル輸送タンパク質活性阻害に有効な置換されたｎ−脂肪族−ｎ−芳香族第三級ヘテロアルキルアミン
EP1154759B1 (fr) 1998-12-30 2008-08-13 Dexcel Ltd. Concentre dispersable destine a l'administration d'une cyclosporine
CO5271716A1 (es) * 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
US6482862B1 (en) * 1999-12-20 2002-11-19 G.D. Searle & Co. Method of using substituted N-benzyl-N-phenyl aminoalcohols for inhibiting cholesteryl ester transfer protein activity
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
ES2284871T3 (es) * 2001-06-22 2007-11-16 Pfizer Products Inc. Composiciones farmaceuticas que contienen una dispersion solida de farmaco poco soluble y un polimero potenciador de la solubilidad.
WO2003000235A1 (fr) * 2001-06-22 2003-01-03 Pfizer Products Inc. Compositions pharmaceutiques de dispersions de medicaments et de polymeres neutres
EP1269994A3 (fr) * 2001-06-22 2003-02-12 Pfizer Products Inc. Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament
AU2002309172A1 (en) * 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
MXPA04007428A (es) * 2002-02-01 2004-10-11 Pfizer Prod Inc Formas de dosificacion de liberacion inmediata que contienen dispersiones de farmaco solido.
ATE395044T1 (de) * 2002-02-01 2008-05-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
KR20050088190A (ko) * 2002-12-20 2005-09-02 화이자 프로덕츠 인코포레이티드 콜레스테릴 에스터 전달 단백질 억제제 및 ｈｍｇ-ｃｏａ환원 효소 억제제를 포함하는 투약 형태
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors

Also Published As

Publication number Publication date
CR7163A (es) 2004-02-23
SK15172003A3 (en) 2004-11-03
BR0210505A (pt) 2004-05-18
PE20030128A1 (es) 2003-02-28
PA8548601A1 (es) 2003-09-05
HN2002000153A (es) 2002-11-05
ECSP034875A (es) 2004-01-28
GT200200124A (es) 2003-09-22
EE200400024A (et) 2004-06-15
CN1635911A (zh) 2005-07-06
US20030022944A1 (en) 2003-01-30
WO2003000295A3 (fr) 2004-05-27
ZA200308561B (en) 2004-11-17
EA200301139A1 (ru) 2004-12-30
US6962931B2 (en) 2005-11-08
NO20035632D0 (no) 2003-12-17
HUP0400263A2 (hu) 2005-03-29
AP2002002559A0 (en) 2002-06-30
CA2455288A1 (fr) 2003-01-03
AR034599A1 (es) 2004-03-03
BG108486A (bg) 2005-03-31
PL368850A1 (en) 2005-04-04
OA12619A (en) 2006-06-12
TNSN03139A1 (fr) 2005-12-23
IS7014A (is) 2003-10-31
MXPA04000014A (es) 2004-05-21
CZ20033341A3 (cs) 2004-10-13
IL158765A0 (en) 2004-05-12
UY27344A1 (es) 2003-01-31
EP1453544A2 (fr) 2004-09-08
SV2003001103A (es) 2003-03-18
KR20040015746A (ko) 2004-02-19
NO20035632L (no) 2004-02-18
WO2003000295A2 (fr) 2003-01-03
US20060014788A1 (en) 2006-01-19
JP2005500314A (ja) 2005-01-06

Similar Documents

Publication Publication Date Title
MA27034A1 (fr) Formulations auto-emulsionnables d'inhibiteurs de la proteine de transfert d'ester de cholesteryle
MA26935A1 (fr) Compositions pharmaceutiques d'inhibiteurs de la proteine de transfert d'ester de cholesteryle
EP1100869A4 (fr) 98 proteines humaines secretees
IS2325B (is) Örgerðar samsetningar epleróns
ATE546139T1 (de) Isoprentransferase proteine inhibitoren
NO20026001D0 (no) 3'-promedikamenter av 2'-deoksy-<Beta>-L-nukleosider
EP1443905A4 (fr) Compositions pour therapie genique orale et procedes d'utilisation associes
EP1377587A4 (fr) Inhibiteurs de proteine phosphate
EP1244683A4 (fr) 21 proteines humaines secretees
NO20020185L (no) Formuleringer av IL-11
MA26882A1 (fr) COMPOSITIONS PHARMACEUTIQUES D'INHIBITEURS ET GLYCOGèNE-PHOSPHORYLASE
NO20015828L (no) Fremgangsmåter for fremstilling av 5'-nukleinsyre- proteinkonjugater
DK1216025T3 (da) Dispersionsformuleringer indeholdende lipaseinhibitorer
EP1044211A4 (fr) 36 proteines humaines secretees
AU2002355551A1 (en) Antisense modulation of cholesteryl ester transfer protein expression
EP1124850A4 (fr) 12 proteines humaines secretees
EP1405912A4 (fr) Ecarine genetiquement modifiee et procede d'elaboration
EP1062236A4 (fr) 31 proteines humaines secretees
EP1163340A4 (fr) Compositions et methodes de modification de l'expression genique
EP1237901A4 (fr) 28 proteines secretees humaines
EP1228082A4 (fr) Proteines humaines secretees 29
ITMI20001987A0 (it) Varianti di proteine allergeniche di phleum pratense
EP1224209A4 (fr) 10 proteines humaines secretees
ITMI990001A0 (it) Mutanti di proteine e plasmidi idonei per la loro sintesi
ITMI20000360A0 (it) Gel orale contenente composti aminoacidi solforati